Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients

被引:2
|
作者
van der Lee, Manon [1 ]
Sankatsing, Roaj
Schippers, Emile
Vogel, Martin
Faetkenheuer, Erd
van der Ven, Andre
Kroon, Frank
Rockstroh, Juegen
Wyen, Christoph
Baeumer, Anselm
de Root, Eric
Koopmans, Peter
Stroes, Erik
Reiss, Peter
Burger, David
机构
[1] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands
[2] Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands
[3] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands
[4] Univ Med Ctr Leiden, Dept Infect Dis, Leiden, Netherlands
[5] Univ Bonn, Dept Internal Med 1, D-5300 Bonn, Germany
[6] Univ Cologne, Dept Internal Med, Cologne, Germany
[7] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Gen Internal Med, Nijmegen, Netherlands
[8] Acad Med Ctr, Dept Infect Dis Trop Med & Aids, Amsterdam, Netherlands
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Lopinavir/ritonavir-containing antiretroviral therapy can cause hyperlipidaemia. However, most statins are contraindicated due to drug-drug interactions. Rosuvastatin undergoes minimal metabolism by CYP450, so no CYP450-based interaction with lopinavir/ritonavir is expected. This study explored the lipid-lowering effect of rosuvastatin and assessed the effect of lopinavir/ritonavir on the pharmacokinetics of rosuvastatin and vice versa. Methods: HIV-infected patients on lopinavir/ritonavir (viral load > 400 copies/ml) with total cholesterol (TC) > 6.2 mmol/l were treated with rosuvastatin for 12 weeks, starting on 10 ring once daily. If fasting target values (TC < 5.0 mmol/l, high-density lipoprotein-cholesterol > 1.0 mmol/l, low-density lipoprotein- cholesterol [LDL-c] < 2.6 mmol/l and triglycerides < 2.0 mmol/1) were not reached, rosuvastatin was escalated to 20 mg or 40 mg at week 4 and 8, respectively. Plasma lopinavir/ritonavir trough levels (C-min) were determined at week 0, 4, 8 and 12 and rosuvastatin C-min, at week 4, 8 and 12. Results: Twenty-two patients completed the study. Mean reductions in TC and LDL-c from baseline to week 4 (on rosuvastatin 10 mg once a day) were 27.6% and 31.8%, respectively. Lopinavir/ritonavir concentrations were not influenced by rosuvastatin (P=0.44 and 0.26, repeated-measures analysis). Median (interquartile range) rosuvastatin C-min, for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70-1.5), 2.5 (1.3-3.3) and 5.5 (3.3-8.8) ng/ml, respectively. Conclusions: Rosuvastatin appeared to be an effective statin in hyperlipidaemic HIV-infected patients. Lopinavir/ritonavir levels were not affected by rosuvastatin, but rosuvastatin levels unexpectedly appeared to be increased 1.6-fold compared with data from healthy volunteers. Until safety and efficacy have been confirmed in larger studies, the combination of rosuvastatin and lopinavir/ritonavir should be used with caution.
引用
收藏
页码:1127 / 1132
页数:6
相关论文
共 50 条
  • [41] Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir
    Bongiovanni, M
    Bini, T
    Cicconi, P
    Landonio, S
    Meraviglia, P
    Testa, L
    Di Biagio, A
    Chiesa, E
    Tordato, F
    Biasi, P
    Adorni, F
    Monforte, AD
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (02) : 132 - 138
  • [42] Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults
    Molto, Jose
    Barbanoj, Manuel Jose
    Miranda, Cristina
    Blanco, Asuncion
    Santos, Jose Ramon
    Negredo, Eugenia
    Costa, Joan
    Domingo, Pere
    Clotet, Bonaventura
    Valle, Marta
    CLINICAL PHARMACOKINETICS, 2008, 47 (10) : 681 - 692
  • [43] Long-term Lopinavir/Ritonavir Monotherapy in HIV-infected Children
    Kosalaraksa, Pope
    Ananworanich, Jintanat
    Puthanakit, Thanyawee
    Pinyakorn, Suteeraporn
    Lumbiganon, Pagakrong
    Chuanjaroen, Thongsuai
    Chobkarjing, Umaporn
    Phanuphak, Praphan
    Pancharoen, Chitsanu
    Bunupuradah, Torsak
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (04) : 350 - 353
  • [44] Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients
    Aarnoutse, RE
    Brinkman, K
    Benetucci, J
    Begovac, J
    Stek, M
    Burger, DM
    AIDS, 2004, 18 (03) : 565 - 567
  • [45] Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients
    Fätkenheuer, G
    Römer, K
    Kamps, R
    Salzberger, B
    Burger, D
    AIDS, 2001, 15 (17) : 2334 - 2335
  • [46] HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir
    Bunupuradah, Torsak
    Bowonwattanuwong, Chureeratana
    Jirajariyavej, Supunnee
    Munsakul, Warangkana
    Klinbuayaem, Virat
    Sophonphan, Jiratchaya
    Mahanontharit, Apicha
    Hirschel, Bernard
    Ruxrungtham, Kiat
    Ananworanich, Jintanat
    ANTIVIRAL THERAPY, 2014, 19 (06) : 579 - 586
  • [47] Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients
    Piscitelli, SC
    Wells, MJ
    Metcalf, JA
    Baseler, M
    Stevens, R
    Davey, RT
    PHARMACOTHERAPY, 1996, 16 (05): : 754 - 759
  • [48] Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis
    Ren, Yuan
    Nuttall, James J. C.
    Egbers, Claire
    Eley, Brian S.
    Meyers, Tammy M.
    Smith, Peter J.
    Maartens, Gary
    McIlleron, Helen M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (05) : 566 - 569
  • [49] Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: the Kaledose trial
    Meynard, Jean-Luc
    Morand-Joubert, Laurence
    Lacombe, Karine
    Poirier, Jean-Marie
    Slama, Laurence
    Valantin, Marc-Antoine
    Girard, Pierre-Marie
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (01) : 125 - 128
  • [50] Study of the Gastrointestinal Tolerance of a New Tablet Formulation of the Lopinavir/Ritonavir Antiretroviral in HIV-Infected Patients
    Saez de la Fuente, Javier
    Granja, Virginia
    Escobar, Ismael
    Collada de la Fuente, Elena
    Moreno, Victor
    Rubio, Rafael
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (03) : 294 - 298